CME Presentations

Anticoagulation


Presentations


Speakers

  • Christian T. Ruff, MD, MPH

    Christian T. Ruff, MD, MPH

    Christian T. Ruff, MD, MPH

    TIMI Study Group

    Christian T. Ruff, MD, MPH, is an associate physician in the Cardiovascular Division at Brigham and Women’s Hospital and an assistant professor of medicine at Harvard Medical School, both in Boston, Massachusetts. His expertise lies in atrial fibrillation, both risk stratification and implementation of antithrombotic therapy for stroke prevention, as well as the treatment and prevention of venous thromboembolism. Dr Ruff is an investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group, is director of the Genetics Core Laboratory, and co-chairman of the Clinical Events Committee. He earned his medical degree at the Johns Hopkins University School of Medicine and his master of public health degree at the Harvard School of Public Health.
  • Elaine Hylek, MD, MPH

    Elaine Hylek, MD, MPH

    Elaine Hylek, MD, MPH

    Director, Thrombosis Clinic & Anticoagulation Service

    Elaine M. Hylek, MD, MPH, is a professor of medicine at Boston University School of Medicine in Boston, Massachusetts. She received her MD from the University of Pittsburgh School of Medicine, her MPH (quantitative methods) from Harvard University School of Public Health, and completed her internal medicine residency training at Massachusetts General Hospital and Harvard Medical School. Dr Hylek’s research areas include arterial (stroke) and venous thrombosis, anticoagulant therapies, and atrial fibrillation. She is a section editor for the Journal of Thrombosis and Haemostasis, a member of the International Society of Thrombosis and Haemostasis Executive Committee for World Thrombosis Day, and director of the Thrombosis and Anticoagulation Service at Boston Medical Center.

CME Information

Bleeding Risk Assessment and Management in Patients Receiving Anticoagulation


LEARNING OBJECTIVES

  • Stratify risk for major bleeding in patients requiring anticoagulation
  • Summarize clinical efficacy and safety data of current and emerging reversal agents for NOAC‐associated bleeds
  • Apply clinical standard of care in the management of bleeding from access to selective anticoagulation reversal agents to effective overall supportive bleeding management strategies
  • Employ best practices for anticoagulation therapy reintroduction

Acknowledgement

This activity is supported by an independent educational grant from Portola Pharmaceuticals, Inc.

Tuition

Complimentary

ACCREDITATION STATEMENT

The activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and PlatformQ Health Education, LLC. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS

Live Internet Activity

Albert Einstein College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material

Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS

The American Academy of Nurse Practitioners (AANP) and American Nurses Credentialing Center (ANCC) accept AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

DATE OF RELEASE/EXPIRATION

Live Internet Activity
Tuesday, December 18, 2018 from 12:00 PM EST – 1:00 PM ET

Enduring Material
The enduring material will be available from December 18, 2018 to June 18, 2019.

Intended Audience

This activity is intended for US‐based hospitalists (including those in emergency medicine, intensive care, and surgery), internal medicine and primary care providers, cardiologists, nurse practitioners, physician assistants, nurses, pharmacists, and other health care providers who care for patients at risk of thromboembolic events.

ESTIMATED TIME TO COMPLETE

This activity consists of one session, which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that this module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE

The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenter

Christian T. Ruff, MD, MPH Consulting Fee: Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Janssen, MedImmune, Pfizer, Portola
Contracted Research: Boehringer Ingelheim, Daiichi Sankyo, MedImmune

Elaine Hylek, MD, MPH
Consulting Fee: Boehringer Ingelheim, Bristol Myers Squibb/Pfizer, Janssen, Medtronic Portola
Scientific Symposia Lecture: Boehringer Ingelheim, Bristol Myers Squibb/Pfizer

Peer Reviewer

Henny Billett, MD
Consulting Fees: Kedrion, BPL Advisory, Bayer
Contracted Research: Janssen

Victor B. Hatcher, PhD
No disclosures to report relevant to this activity

Providers

Einstein–Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine has no disclosures to report relevant to this activity.

PlatformQ Health Education, LLC

Joe Chebli, PharmD, Medical Director Has nothing to disclose relevant to this activity.

Alissa Yost, Senior Program Manager Has nothing to disclose relevant to this activity.

Contact Information

Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Support@CardioCareLive.com.

DISCLAIMERS (if applicable):

The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Albert Einstein College of Medicine, CardioCareLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.